Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical...
share announcement

Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1079

Special Issue Editor

Dr. Cristel Ruini

E-Mail Website
Guest Editor
Department of Dermatology and Allergy, University Hospital, LMU Munich, 80336 Munich, Germany
Interests: dermatology; dermatosurgery; dermato-oncology; melanoma and non-melanoma skin cancer; non-invasive diagnostics in dermatology

Special Issue Information

Dear Colleagues,

Welcome to this Special Issue of our scientific journal, titled "Advances in Skin Cancer Diagnostic and Therapy: Research and Clinical Studies".

Skin cancer remains a significant global health concern. Not only melanoma, but also less deadly non-melanoma skin cancer (NMSC) continues to increase in incidence in the general population and to pose challenges in both research and clinical practice. In this collection of articles, we aim to bring together leading experts in the field of skin cancer and their diagnostic methods to share their groundbreaking findings. These articles will mainly focus on the ever more important connection of novel diagnostic tools, clinical applications and artificial intelligence in a multidisciplinary context. Thank you for joining us on this journey aiming to provide readers with a comprehensive overview of the latest advancements in this field.

Dr. Cristel Ruini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-melanoma skin cancer
  • melanoma
  • actinic keratosis
  • field cancerisation
  • medical diagnostics
  • dermatology
  • dermoscopy
  • optical coherence tomography
  • in vivo confocal microscopy
  • ex vivo confocal microscopy
  • artificial intelligence

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 8612 KiB  
Article
Ex Vivo Confocal Laser Scanning Microscopy in Rare Skin Diseases
by Luis Messner, Maximilian Deußing, Michaela Maurer, Lisa Buttgereit, Lara Stärr, Lars E. French and Daniela Hartmann
Cancers 2024, 16(9), 1713; https://doi.org/10.3390/cancers16091713 - 28 Apr 2024
Viewed by 131
Abstract
While ex vivo confocal laser scanning microscopy has previously demonstrated its utility in most common skin diseases, its use in the assessment of dermatological entities with lower incidence remains unexplored in most cases. We therefore aimed to evaluate the diagnostic efficacy of some [...] Read more.
While ex vivo confocal laser scanning microscopy has previously demonstrated its utility in most common skin diseases, its use in the assessment of dermatological entities with lower incidence remains unexplored in most cases. We therefore aimed to evaluate the diagnostic efficacy of some rare skin tumors as well as a few inflammatory skin diseases, that have not yet been studied in ex vivo confocal laser scanning microscopy. A total of 50 tissue samples comprising 10 healthy controls, 10 basal cell carcinoma, 10 squamous cell carcinoma, and 20 rare skin conditions were imaged using the newest generation ex vivo confocal microscopy (Vivascope 2500 M-G4, Vivascope GmbH, Munich, Germany). Three blinded investigators were asked to identify characteristic features of rare skin disorders and distinguish them from more common skin diseases in the ex vivo confocal microscopy images. Our findings present the capability of ex vivo confocal microscopy to display distinctive morphologic patterns in common and rare skin diseases. As might be expected, we found a strong correlation between imaging experience and diagnostic accuracy. While the imaging inexperienced dermatohistopathologist reached 60% concordance, the imaging-trained dermatologist obtained 88% agreement with dermatohistopathology. The imaging-trained dermatohistopathologist achieved concordance up to 92% with gold-standard dermatohistopathology. This study highlights the potential of ex vivo confocal laser scanning microscopy as a promising adjunct to conventional dermatohistopathology for the early and precise identification of rare dermatological disorders. Full article
(This article belongs to the Special Issue Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies)
►▼ Show Figures

Figure 1

11 pages, 2736 KiB  
Article
Electrochemotherapy in Kaposi’s Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions
by Vincenzo Rullo, Francesco Castellaneta, Santolo D’Antonio, Anna De Rosa, Michele Pio Grieco and Tommaso Fabrizio
Cancers 2024, 16(7), 1295; https://doi.org/10.3390/cancers16071295 - 27 Mar 2024
Viewed by 464
Abstract
Electrochemotherapy (ECT) is one of the newest therapeutic strategies employed as a medical procedure for skin neoplasms’ treatment, especially for classic Kaposi’s sarcoma (CKS). The aim of this study was to demonstrate ECT clinical response and the local control of CKS disease. The [...] Read more.
Electrochemotherapy (ECT) is one of the newest therapeutic strategies employed as a medical procedure for skin neoplasms’ treatment, especially for classic Kaposi’s sarcoma (CKS). The aim of this study was to demonstrate ECT clinical response and the local control of CKS disease. The primary endpoint was to value the worth and efficacy of this local therapy in CKS skin lesions’ treatment. In total, 19 CKS patients were enrolled, 14 males and 5 females with median age at diagnosis of 72. Complete response (CR) has been gained in 12 patients after first ECT attempt; meanwhile, 3 and 4 out of 19 patients obtained a partial response (PR), so they underwent a second and third ECT treatment, respectively. Clinical response was evaluated during the entire timeframe of the follow-up, which ranged between 3 months and 4 years with a median of 18 months. The control of CKS skin lesions still represents a challenge for surgeons and oncologists. Nevertheless, according to this and other authors’ recent experiences, ECT could be considered the gold standard strategy for early-stage patients, but at the same time it could be considered as a valid option in controlling Kaposi’s sarcoma locally advanced lesions. Full article
(This article belongs to the Special Issue Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1859 KiB  
Review
A Systematic Review and Meta-Analysis on the Diagnostic and Prognostic Values of 18F-FDG PET in Uveal Melanoma and Its Hepatic Metastasis
by Seyed Ali Mirshahvalad, Nazanin Zamani-Siahkali, Christian Pirich and Mohsen Beheshti
Cancers 2024, 16(9), 1712; https://doi.org/10.3390/cancers16091712 - 28 Apr 2024
Viewed by 143
Abstract
In this systematic review and meta-analysis (PRISMA-compliant), we tried to investigate diagnostic and prognostic values of 18F-FDG PET in uveal melanoma. A systematic search was conducted on the main medical literature databases to include studies that evaluated 18F-FDG PET as the [...] Read more.
In this systematic review and meta-analysis (PRISMA-compliant), we tried to investigate diagnostic and prognostic values of 18F-FDG PET in uveal melanoma. A systematic search was conducted on the main medical literature databases to include studies that evaluated 18F-FDG PET as the imaging modality to evaluate patients with uveal melanoma. Overall, 27 studies were included. Twelve had data about the detection rate of 18F-FDG PET in primary intra-ocular tumours. The pooled sensitivity was 45% (95%CI: 41–50%). Furthermore, studies showed that the larger the primary tumour, the higher its uptake. Among the included studies, 13 assessed 18F-FDG PET in detecting metastasis. The pooled sensitivity and specificity were 96% (95%CI: 81–99%) and 100% (95%CI: 94–100%), respectively. Regarding liver metastasis, they were 95% (95%CI: 79–99%) and 100% (95%CI: 91–100%), respectively. Noteworthy, the level of 18F-FDG uptake was a strong predictor of patient survival. Lastly, 18F-FDG PET could characterise lesions from the histopathology perspective, distinguishing high-risk from low-risk diseases. Overall, although not reliable in detecting primary intra-ocular tumours, 18F-FDG PET is highly accurate for diagnosing metastatic uveal melanomas. It can also be a highly valuable modality in terms of patient prognostication. Thus, 18F-FDG PET can be recommended in patients diagnosed with uveal melanoma to enhance decision-making and patient management. Full article
(This article belongs to the Special Issue Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop